- Home
- SKIL vs ATOS Comparison
SKIL vs ATOS Comparison
Compare SKIL & ATOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SKIL | ATOS |
|---|---|---|
| Founded | 1998 | 2009 |
| Country | United States | United States |
| Employees | 2247 | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 40.2M | 36.2M |
| IPO Year | N/A | 2010 |
Fundamental Metrics
Financial Performance| Metric | SKIL | ATOS |
|---|---|---|
| Price | $6.25 | $4.51 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $23.00 |
| AVG Volume (30 Days) | ★ 55.6K | 40.2K |
| Earning Date | 04-07-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $1,758.00 |
| Revenue This Year | $0.11 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $3.43 | $0.53 |
| 52 Week High | $18.45 | $7.56 |
Technical Indicators
Market Signals| Indicator | SKIL | ATOS |
|---|---|---|
| Relative Strength Index (RSI) | 38.82 | 37.14 |
| Support Level | $3.63 | $3.80 |
| Resistance Level | $8.48 | $6.18 |
| Average True Range (ATR) | 0.64 | 0.27 |
| MACD | -0.16 | -0.05 |
| Stochastic Oscillator | 12.04 | 17.97 |
Price Performance
Historical ComparisonAbout SKIL Skillsoft Corp.
Skillsoft Corp is a leader in corporate digital learning. The company's segments include Talent Development Solutions and Global Knowledge. Talent Development Solutions brings a foundation of products and customers. TDS enterprise-grade solution serves customers and employees world-wide. TDS Learner is a world-renowned consumer-scale and experiential learning platform that serves learners internationally. The Global Knowledge segment is centered around instructor-led training, or live learning, with face-to-face delivery by experienced trainers, both in-person and virtually.
About ATOS Atossa Therapeutics Inc.
Atossa Therapeutics Inc is a clinical stage biopharmaceutical company developing proprietary medicines in areas of unmet medical need in oncology. It focuses on the development of novel therapeutics and delivery methods for the treatment of breast cancer, other breast conditions and COVID-19. The company's drug under development for breast cancer and other breast conditions is Endoxifen. Its two COVID-19 drugs under development are AT-H201, to improve lung function of moderate to severely ill, hospitalized COVID-19 patients by inhalation; and AT-301, a nasal spray for COVID-19 patients for at-home use.